Telix maintains an active role in supporting policy and legislative measures that foster innovation and enhance patient access to nuclear medicine. Our commitment to improving healthcare systems is demonstrated through our strategic involvement in several key coalitions. As a member of Nuclear Medicines Europe, we advocate on critical issues relating to EU Pharmaceutical Legislation. We are also proud to be one of 123 organizations, alongside industry partners, patient organizations, and medical societies, working collaboratively on the FIND Act in the United States. In Australia, we contribute meaningfully to the Federal Health Technology Assessment Review through both written submissions and direct participation in in-person consultations. These engagements reflect our dedication to advancing global healthcare accessibility and innovation in nuclear medicine.